ArticleDiscover oncology2025
The influence of RAD51 (rs1801320) on breast cancer risk: an updated meta-analysis.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The Genetic Polymorphisms of DNA Repair Gene RAD51 and Their Role as a Predictive Biomarker for Breast Cancer Risk and Response to Radiotherapy in Iraqi Women.Asian Pacific journal of cancer prevention : APJCP · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDNA repair mechanisms, particularly RAD51-mediated homologous recombination repair, play a crucial role in breast cancer development, with the rs1801320 (135G > C) polymorphism showing conflicting associations across studies. This meta-analysis aimed to assess the relationship between RAD51 rs1801320 polymorphism and breast cancer susceptibility.
methodWe systematically searched PubMed and Web of Science databases through August 15, 2024, and included 16 case-control studies comprising 4743 breast cancer cases and 4448 controls, analyzing various genetic models using R Studio.
resultsOur results revealed significant associations in several genetic models: the allele contrast model (C vs. G) showed an increased risk (OR = 1.37, 95% CI: 1.04-1.80, p = 0.0249. The recessive model (CC vs. CG + GG) demonstrated a strong risk association (OR = 2.68, 95% CI: 1.55-4.61, p = 0.00038), while the dominant model (CC + CG vs. GG) showed no significant association (OR = 1.12, 95% CI: 0.98-1.28, p = 0.1037). Pairwise comparisons revealed the CC genotype as a substantial risk factor, particularly in CC vs. GG (OR = 2.31, 95% CI: 1.58-3.37, p = 0.00001) and CC vs. CG (OR = 2.97, 95% CI: 1.53-5.77, p = 0.00128) comparisons. Most models showed moderate to high heterogeneity (I
conclusionThis comprehensive meta-analysis is larger than previous studies and provides robust evidence that the RAD51 rs1801320 CC genotype significantly increases breast cancer risk, particularly in recessive and homozygous comparison models, suggesting potential implications for cancer risk assessment and therapeutic strategies targeting DNA repair mechanisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.